Globus Medical, Inc. cash flow to debt ratio of 634.98% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Globus Medical, Inc.'s free cash flow has increased 45.30% from $405.21M last year to $588.77M, signaling increasing performance

Globus Medical, Inc.'s debt to equity ratio is 0.02, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Globus Medical, Inc.'s debt has decreased relative to shareholder equity from 0.13 last year to 0.02 today, signaling strengthened financials

Globus Medical, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Globus Medical, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Globus Medical, Inc.'s profit margin has increased (362.93%) in the last year from 4.09% to 18.92%, signaling increasing performance

Globus Medical, Inc.'s short-term assets of $2.13G exceed its short-term liabilities of $498.50M

Globus Medical, Inc.'s return on assets of 10.79% is higher than the 5.00% threshold, indicating efficient asset utilization

Globus Medical, Inc.'s return on equity of 13.04%, is lower than 15.00%, indicating bad performance

Globus Medical, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Globus Medical, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings

Globus Medical, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Globus Medical, Inc. has a free cash flow yield of 5.06%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Globus Medical, Inc.'s yearly earnings has increased 422.31% since last year from $102.98M to $537.90M, signaling increasing performance

Globus Medical, Inc.'s yearly revenue has increased 16.65% since last year from $2.52G to $2.94G, signaling increasing performance

ROIC 9.72% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.

Globus Medical, Inc.'s 3-year revenue CAGR of 42.16% is positive, indicating growing revenue over the past 3 years

Globus Medical, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Globus Medical, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity

Globus Medical, Inc. is overvalued relative to its fair value price of 80.29 based on Discounted Cash Flow model

Globus Medical, Inc. has an earnings yield of 5.03%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Globus Medical, Inc. is overvalued relative to its fair value price of 40.79 based on EBITDA multiple model

Globus Medical, Inc. has an EV/EBITDA ratio of 12.71x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Globus Medical, Inc. is overvalued relative to its fair value price of 70.11 based on Earnings Fair Value model

Globus Medical, Inc. has a PEG-ratio under 1 which is considered undervalued

Globus Medical, Inc. has a price-to-book ratio of 2.47x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Globus Medical, Inc. has a price-to-sales ratio of 3.75x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue